Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="FERSTER, A" or (type any "bookEditor issueEditor" and editor="FERSTER, A")

Add to list
Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia : results of the EORTC CLG 58881 and 58951 trials

C Piette, S Suciu, E Clappier, Y Bertrand, S Drunat, S Girard, K Yakouben, G Plat, N Dastugue, F Mazingue, et al.

(2018) LEUKEMIA. 32(1). p.244-248
Add to list
IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Chrildren's Leukemia Group study 58951

E Clappier, N Grardel, M Bakkus, J Rapion, Barbara De Moerloose (UGent) , P Kastner, A Caye, J Vivent, V Costa, A Ferster, et al.

(2015) LEUKEMIA. 29(11). p.2154-2161
Add to list
Minimal residual disease quantification by PCR in childhood acute lymphoblastic leukaemia

J Van der Straeten, Barbara De Moerloose (UGent) , MF Dresse, S Dupont, A Ferster, P Philippet, A Uyttebroeck, J van der Werff ten Bosch, C Demanet, Yves Benoit (UGent) , et al.

(2014) BELGIAN JOURNAL OF HEMATOLOGY. 5(3). p.81-88
Add to list
Impact of minimal residual disease monitoring on therapy in Belgian childhood acute lymphoblastic leukaemia

J Van der Straeten, Barbara De Moerloose (UGent) , MF Dresse, S Dupont, A Ferster, P Philippet, A Uyttebroeck, J van der Werff ten Bosch, C Demanet, Yves Benoit (UGent) , et al.

(2014) Belgian Hematological Society, 29th General annual meeting, Abstracts.
Add to list
An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions

E Clappier, M-F Auclerc, J Rapion, M Bakkus, A Caye, A Khemiri, C Giroux, L Hernandez, E Kabongo, S Savola, et al.

(2014) LEUKEMIA. 28(1). p.70-77
Add to list
- Conference Paper
- C3
- open access
Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies in paediatric patients with primary immunodeficiency disease (PID) treated with intravenous immunoglobulin (Multigam®)

D Tuerlinckx, B Florkin, I de Schutter, C Chantrain, Filomeen Haerynck (UGent) , P Philippet, R Laub and A Ferster

(2012) JOURNAL OF CLINICAL IMMUNOLOGY. 32(suppl. 1). p.136-137
Add to list
- Conference Paper
- C3
- open access
Quantifying total IgG and IgG subclasses (peak and trough) in primary immunodeficiency paediatric patients treated with intravenous immunoglobulin (Multigam®) and relation with serospecific antipneumococcal antibodies

D Tuerlinckx, B Florkin, I de Schutter, C Chantrain, Filomeen Haerynck (UGent) , P Philippet, R Laub and A Ferster

(2012) JOURNAL OF CLINICAL IMMUNOLOGY. 32(suppl. 1). p.158-158
Add to list
- Conference Paper
- C3
Presentation and outcome of children with down syndrome and acute lymphoblastic leukemia in the eortc children's leukemia group protocol 58951

Veerle Mondelaers (UGent) , Barbara De Moerloose (UGent) , S Suciu, A Ferster, P Lutz, A Uyttebroeck, D Plantaz, L Norton, N Sirvent, A Robert, et al.

(2010) HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. 95(Suppl. 2). p.260-260
Add to list
- Journal Article
- A1
Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia

F CORAZZA, C HERMANS, S D'HONDT, A FERSTER, A KENTOS, Yves Benoit (UGent) and E SARIBAN

(2006) BLOOD. 107(6). p.2525-2530
Add to list
- Conference Paper
- C3
Prognostic significance of blasts with/without pleiocytosis in the cerebro-spinal fluid (CSF) of children with acute lymphoblastic leukemia (ALL) treated without cranial irradiation: results of European Organization for Research and Treatment of Cancer (EORTC) children leukemia group study 58881

N Sirvent, S Suciu, X Rialland, A Robert, F Mazingue, F Millot, Barbara De Moerloose (UGent) , A Ferster, P Rohrlich, L Norton, et al.

(2006) Blood. 108(11). p.A149-A149

Academic Bibliography

Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia : results of the EORTC CLG 58881 and 58951 trials

IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Chrildren's Leukemia Group study 58951

Minimal residual disease quantification by PCR in childhood acute lymphoblastic leukaemia

Impact of minimal residual disease monitoring on therapy in Belgian childhood acute lymphoblastic leukaemia

An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions

Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies in paediatric patients with primary immunodeficiency disease (PID) treated with intravenous immunoglobulin (Multigam®)

Quantifying total IgG and IgG subclasses (peak and trough) in primary immunodeficiency paediatric patients treated with intravenous immunoglobulin (Multigam®) and relation with serospecific antipneumococcal antibodies

Presentation and outcome of children with down syndrome and acute lymphoblastic leukemia in the eortc children's leukemia group protocol 58951

Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia

Prognostic significance of blasts with/without pleiocytosis in the cerebro-spinal fluid (CSF) of children with acute lymphoblastic leukemia (ALL) treated without cranial irradiation: results of European Organization for Research and Treatment of Cancer (EORTC) children leukemia group study 58881

Contents

Support

Contact